ASTCT

How should clinicians navigate donor selection in an increasingly complex transplantation landscape?

In this Nucleus Q&A, Antonio Jiménez-Jiménez, MD, discusses the latest NMDP/CIBMTR recommendations for allogeneic hematopoietic cell donor selection, including advances in HLA matching, donor characteristics, graft source considerations, and key factors shaping donor selection decisions in contemporary practice. Read the interview: ow.ly/r6HK5105aY3

Why pay full price for #Tandem27? Register before Nov. 20 to access the best rates for your full team.
Register today: ow.ly/RNon5105aWp

As we approach the Thanksgiving season, Margy MacMillan, MD, MSc, FRCPC, reminds us of the privilege of caring for patients and the power of the community that makes transplantation and cellular therapy possible.

Read on Nucleus the latest President’s Message on gratitude, collaboration, and the shared mission that drives ASTCT members every day. ow.ly/YoJ45105aNF

ASTCT is now accepting Volunteer applications for multiple committees making an impact across the Society.
The Call for Volunteers closes soon on Nov. 13.
Learn more and submit your interest: ow.ly/kvg75105aI2

As cellular therapies expand across hematologic malignancies, solid tumors, and autoimmune diseases, understanding and managing treatment-related toxicities has never been more important.

In this Healio Q&A, Sergio A. Giralt, MD, FACP, FASTCT discusses the upcoming 5th International Conference on Toxicities of Transplantation and Cellular Therapies taking place on Nov. 13-14 in Chicago, highlighting emerging toxicities, multidisciplinary approaches to toxicity management, care for older adults, and the research needed to improve the safety and tolerability of transplantation and cellular therapies.

Read more: ow.ly/BF225105atL